P
Peter Kovar
Researcher at AbbVie
Publications - 51
Citations - 5194
Peter Kovar is an academic researcher from AbbVie. The author has contributed to research in topics: CHEK1 & Kinase. The author has an hindex of 27, co-authored 49 publications receiving 4514 citations.
Papers
More filters
Journal ArticleDOI
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers,Joel D. Leverson,Erwin R. Boghaert,Scott L. Ackler,Nathaniel D. Catron,Jun Chen,Brian D. Dayton,Hong Ding,Sari H. Enschede,Wayne J. Fairbrother,David C.S. Huang,David C.S. Huang,Sarah G. Hymowitz,Sha Jin,Seong Lin Khaw,Seong Lin Khaw,Peter Kovar,Lloyd T. Lam,Jackie Lee,Heather Maecker,Kennan C. Marsh,Kylie D. Mason,Kylie D. Mason,Kylie D. Mason,Michael J. Mitten,Paul Nimmer,Anatol Oleksijew,Chang H. Park,Cheol-Min Park,Cheol-Min Park,Darren C. Phillips,Andrew W. Roberts,Andrew W. Roberts,Andrew W. Roberts,Deepak Sampath,John F. Seymour,John F. Seymour,Morey L. Smith,Gerard M. Sullivan,Stephen K. Tahir,Chris Tse,Michael D. Wendt,Yu Xiao,John Xue,Haichao Zhang,Rod A. Humerickhouse,Saul H. Rosenberg,Steven W. Elmore +47 more
TL;DR: The re-engineering of navitoclax is reported to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199, which inhibits the growth of BCL–dependent tumors in vivo and spares human platelets, indicating that selective pharmacological inhibition of Bcl-2 shows promise for the treatment of B CL-2-dependent hematological cancers.
Journal ArticleDOI
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson,Darren C. Phillips,Michael J. Mitten,Erwin R. Boghaert,Dolores Diaz,Stephen K. Tahir,Lisa D. Belmont,Paul Nimmer,Yu Xiao,Xiaoju Max Ma,Kym N Lowes,Kym N Lowes,Peter Kovar,Jun Chen,Sha Jin,Morey L. Smith,John Xue,Haichao Zhang,Anatol Oleksijew,Terrance J. Magoc,Kedar S. Vaidya,Daniel H. Albert,Jacqueline M. Tarrant,Nghi La,Le Wang,Zhi-Fu Tao,Michael D. Wendt,Deepak Sampath,Saul H. Rosenberg,Chris Tse,David C.S. Huang,David C.S. Huang,Wayne J. Fairbrother,Steven W. Elmore,Andrew J. Souers +34 more
TL;DR: BCL-XL–selective inhibitors have the potential to enhance the efficacy of docetaxel in solid tumors and avoid the exacerbation of neutropenia observed with navitoclax, and demonstrate the translational utility of this toolkit of selective BCL-2 family inhibitors.
Journal ArticleDOI
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Joel D. Leverson,Haichao Zhang,Jun Chen,Stephen K. Tahir,D.C. Phillips,John Xue,Paul Nimmer,Sha S. Jin,Morey L. Smith,Yu Xiao,Peter Kovar,Atsushi Tanaka,Milan Bruncko,George S. Sheppard,Leyu Wang,Sarah Gierke,Lorna Kategaya,Daniel Anderson,Chihunt Wong,Jeffrey Eastham-Anderson,Mary J. C. Ludlam,Deepak Sampath,Wayne J. Fairbrother,Ingrid E. Wertz,Saul H. Rosenberg,Chris Tse,Steven W. Elmore,Andrew J. Souers +27 more
TL;DR: This work represents the first description of small-molecule MCL-1 inhibitors with sufficient potency to induce clear on-target cellular activity, and demonstrates the utility of these molecules as chemical tools for dissecting the basic biology of M CL-1.
Journal ArticleDOI
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
Zhi-Fu Tao,Lisa A. Hasvold,Le Wang,Xilu Wang,Andrew M. Petros,Chang H. Park,Erwin R. Boghaert,Nathaniel D. Catron,Jun Chen,Peter M. Colman,Peter E. Czabotar,Kurt Deshayes,Wayne J. Fairbrother,John A. Flygare,Sarah G. Hymowitz,Sha Jin,Russell A. Judge,Michael F. T. Koehler,Peter Kovar,Guillaume Lessene,Michael J. Mitten,Chudi Ndubaku,Paul Nimmer,Hans E. Purkey,Anatol Oleksijew,Darren C. Phillips,Brad E. Sleebs,Brian J. Smith,Morey L. Smith,Stephen K. Tahir,Keith G. Watson,Yu Xiao,John Xue,Haichao Zhang,Kerry Zobel,Saul H. Rosenberg,Chris Tse,Joel D. Leverson,Steven W. Elmore,Andrew J. Souers +39 more
TL;DR: A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses and represents an excellent tool molecule for studying BCL-XL biology as well as a productive lead structure for further optimization.
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208
Souers Andrew J,Joel D. Leverson,Erwin R. Boghaert,Scott L. Ackler,Nathaniel D. Catron,Jun Chen,Brian D. Dayton,Hong Ding,Sari H. Enschede,Wayne J. Fairbrother,David C. S. Huang,Sarah G. Hymowitz,Sha Jin,Seong Lin Khaw,Peter Kovar,Lloyd T. Lam,Jackie Lee,Heather Maecker,Kennan C. Marsh,Kylie D. Mason,Michael J. Mitten,Paul Nimmer,Anatol Oleksijew,Chang H. Park,Cheol-Min Park,Darren C. Phillips,Andrew W. Roberts,Deepak Sampath,John F. Seymour,Morey L. Smith,Gerard M. Sullivan,Stephen K. Tahir,Chris Tse,Wendt Michael D,Yu Xiao,John Xue,Haichao Zhang,Rod A. Humerickhouse,Saul H. Rosenberg,Steven W. Elmore +39 more